The latest update is out from Kiromic Biopharma (KRBP).
Kiromic BioPharma, Inc. has reached an agreement to transform $7.2 million of its high-interest debt plus accrued interest into preferred stock, creating a more favorable capital structure and potentially enhancing shareholder value. Additionally, the company has issued a new convertible note for the converted interest, further simplifying its financial commitments. These strategic moves, coupled with the creation of a new Series D Preferred Stock with dividend rights and liquidation preferences, offer investors an opportunity to engage with Kiromic’s evolving financial landscape, which aims to balance growth prospects with financial stewardship.
For a thorough assessment of KRBP stock, go to TipRanks’ Stock Analysis page.
